COMPANY REGISTRATION NUMBER: N1631937
CHARITY REGISTRATION NUMBER: NIC105452
Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Financial Statements
31 March 2025
Finegan Gibson Ltd
Chartered accountants & statutory auditor
Causeway Tower
9 James Street South
Belfast
BT2 8DN

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Flnancial Statements
Year ended 31 March 2025
Page
Trustees, annual report (incorporating the directorfs report)
Independent auditovs report to the members
Statement of financial activities (including income and
expenditure account)
13
Statement of financial position
14
statement of cash flows
15
Notes to the financial statements
16

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Trustees, Annual Report (Incorporating the Directors, Report)
Year ended 31 March 2025
The trustees. who are also the directors for the purposes of Company law, present thelr report and the
financial statements of the charity for the year ended 31 March 2025.
Roferenca and admlnlstrativo dolails
Registered ¢harlty namo
Leukaemia & Lymphoma Nl
Charity registration number
105452
Company registration number N1631937
Principal offi¢• and rogistorod Patrick G Johnston
offico
Centre for Cancer Research and Cell Biology
97 Lisburn Road
Belfast
BT9 7AE
The trustses
Mr R Buchanan
Mrs E Armstrong
Mr M Cafolla
Ms L Cascone
Mr R Cascone
Mr G Coulter
Mrs J Fairli&Vogt
Mr B Garland
Ms A Greenfield
Ms A Keamey
Professor T Lappin
Mr R McGeough
Dr D Montgomery
Professor T Morris
Miss E Thompson
{appointed 1 May 2025)
(resigned 7 September 2025)
(appointed 1 May 2025)
(appointed 24 June 2025)
Auditor
Finegan Gibson Ltd
Chartered accountants & statutory auditor
Causeway Tower
g James Slreel South
Belfast
BT2 8DN
Bankers
Danske Bank
PO Box 183
Donegall Square West
Belfast
BT16JS
Solicitors
Edwards & Co
28 Hill Street
Belfast
BT12L4

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Trustees. Annual Report (Incorporating the Directors. Report) (continued)
Year ended 31 March 2025
structure, governance and management
The directors have pleasure in submitting their annual report together wth the audiied financial
statements of Leukaemia & Lymphoma Nl (LLNI) for the year ended 31 March 2025.
The directors have adopted the provisions of Ihe Charities SORP (FRS 102) in preparing their annual
report and financial statements ofthe charity.
Legal and administrative information on page 1 forms part of this report.
The charity is govemed by a board of 12 directors throughout the year. Their task, in conjunction with
the staff of the charity, is to oversee the administration of the charity. safeguard its assets and resour¢es
to ensure that they are used solely in the furtherance of the objectives of the charity, and to act in the
best interests of the charity at all limes. Board meetings typically take place eight times per year, with
various Suk￿ComMitteeS also meeting.
All Trustees give of theirtime freely and none received remuneration or expenses. No staff are employed
direcdy by the charity. Instead LLNI pays grants to Queen'5 University to ¢overthe salaries of employees
working on behalf of LLNI.
Rlsk managomant
The major risks to which LLNI would be exposed are cenlred around the following areas..
Reputational risk through invotvement with individuals or organisations that could bring LLNI
into disrepute and the￿fore affect income from donations. The board keeps this under close
review, working wth slaff, to ensure due diligence in all engagement.
Significant ￿dUCtiOn in funding. The board is well aware of the erratic nature of some types of
fundraising. for example the unpredictability of major grfts and legacies, and also grants from
various bodies. This is taken inlo account vthen considering future funding commitments and
LLNI'S financial reseNes.
Mlsuse and misappropriation of funds coupled vllth poor financial ¢ontrol$. The funds to support
research are carefully controlled by the Board of LLNI. which received a financial report by the
honorary treasurer at each meeting of the Board.
Iv.
Lack of proper public liability insurance to cover fund raising activities by members and Ihe
possibility of legal action against members. Fundraising activities are covered for public liability
by LLNI'S insurance brokers. Those tssked by LLNI wth raising funds for LLNI are reminded
that any activity which has the slightest element of risk must have the approval of the insurers
before proceeding. High risk activitie5 are not pennitted.
Objoctivos and activities
Our main objective is to raise money to finance research into the causes and p055ible cures for
leukaemia. lymphoma. myeloma and other associated blood cancers with the aim to improve out¢ome$
and quality of life for this patient group. We fund this research wtth charitable activities, legacy income,
corporate support and external grants, all of which are detailed in the report below. The research that
we fvnd is overseen by LLNI'S Scientific and Medical Advisory Committee (SMACI, with Dr Aaron
Niblo¢k as chair, assisted by a group of experienced academics. Research projects are carefully
scrutinised and "peer reviewed" by the SMAC before any recommendations are made for fijndlng by
LLNI.

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Trustees, Annual Report (Incorporating the Directors, Report) (conllnuedj
Year ended 31 March 2025
strntegic report
The following sections for achievements and performance and financial review form the strategic report
of the charity.
Achievements and perforniance
1. The charity has continued to evolve and expand its influence over the year, whilst maintaining focus
on the core activty of funding blood cancer research in Northern Ireland. Income for the year was
£470,703, which is down on the previous year. This is broadly due to much reduced grant income, which
is not fully predictable from year to year. The board is aware of this, and plans accordingty. Staff at the
charity put considerable effort into making sure we are in a position to apply for research grant funds as
and when they a￿ available. In addition, there is much ongoing work into encouraging legacies and
major gifts. Vvhilst not bearing significant results in the period covered by this report, the indications are
that figures for 2025126 will show clear progress. The undertying income from fvndraising activity and
events is continuing to trend upwards. due to the hard work and focus of the staff team. This is despite
the wider operating environment for all charities remaining challenging. We continue to expand our
nebNork and seek out innovatTve ways of raising funds and building our overall supporter base. Our
prudent reserves policy means that the charity is able to deal with the erratic nature of charty
fvndraising. thus allowing us to maintain funding for vital blood cancer research here in Belfast at the
Johnston Cancer Research Centre (JCRC} and at other institutions.
2. LLNI is fvlly committed to its core mission of raising money to fund blood cancer ￿SearCh, to improve
survival rates and quality of life for blood cancer patients. We are the only Charity in Northem Ireland
solely focused on this. We do this by supporting clinicians, scientists and students researching these
Cancers in Northern Ireland and on occasion in Ireland. when linked to research in Northem I￿land.
This takes place under the oversight of the LLNI direclors, who make up our board and who do it on
voluntary {non-Temunerated) basis. We meet around eighttimes per yearto review all areas of business,
th particular focus on finance, fundraising, scientific progress and an ovetview of the govemance of
the charity- The board remains particularly focused on ensuring that we are complying fully with relevant
legislation and guidance trom the Charity Commission for Northern Ireland. Good goveman¢e is key to
the smooth and effective running of any charity, and we are no exception.
3. The board relies on the Scientific and Medical Advisory Committee (SMAC). chaired by Dr Aaron
Niblock to advise on which reSe8￿h applications should be supported, and thus optimise decision
making. We will aiways consider allematwe or joint means of funding, in a constant drive to make best
use of our funds.
4. In previous recent years our income was significantly boosted by grants from the Medical Researth
Council through the Associalion of Medical Research Charitie$ (AMRC). In previous years this funding
has been available to partty cover the costs of early career scientists that we fund. We will re-apply for
this funding as and when this becomes available again.
5. We are an efficient charity. wth a large proportion of money raised being spent directly on research.
Our relationship with Queen's University 15 immensely valuable to LLNI, and also, we believe to Queen's.
We have a small office in the JCRC, which enables LLNI to maintain a very strong relationship with the
university and our team of dedicated scientists. We are extremely grateful to the management team at
the JCRC for their ongoing sUPPOrt for LLNI and its fundraising for blood cancer research. We remain
Ily open to funding applications from research institLrtions otherthan the JCRC, more than one of which
is currentty progressing.

Leukaemia & Lymphoma Nl
Company Limitsd by Guarantee
Trustees. Annual Report (Incorporating the Directors, Report) (￿l(l￿ut￿)
Year ended 31 March 2025
Achievem8nts and pèrforn)ance {continued>
6. The day to day running of the charity 1$ looked after by Operations Manager Joanne Badger, the
Fundraising manager Tanya Mayne with Claire Gilmore supporting the team. Joanne Badger went on
Maternity Leave at the very end of the period covered by this report, with Stephanie Mcmullan Currenty
covering. All of the team do an outstanding job both in the office, through raising awareness and support
on social media and supporting in person around the country at events and wlh supporters. It makes a
real difference to have our office based in the same building where much of our funded research is
taking place, allowing us to easily demonslrate to supporters exactty Vthe￿ the money raised is going
and to introduce the scientists we fund.
7. As ever, our fundraisers are key to what we do and support from across Northern Ireland has been
both essential and heatharming. The key event forthe year was our 60th Anniversary Ball atthe Belfast
Titanic Centre in September, during Blood Cancer Awareness month. This raised over £100,000 which
is a truly remarkable amount for 8 single event. There are too many people to thank for this and other
events from the year. but Sam and Eleanor Orr deserve special mention for their key support for the
Ball and other events. They and so many others really have made a difference. Our online presen¢e
continues to develop and improve, with an update to the website during the year to make it easier to
navigate. both for supporters and our staff. It is a great improvement on the previous Site, and was
money well spent.
8. Our patron Ken Reid. fonnerly of UTV and a very well-known figure in the Nothern Irish media, sadly
died in November 2024. He had personal experience of a chronic leukaemia, and it was sad to see the
passing of such a wonderful man. His SUPPOrt for LLNI wa5 really powerful and he is greatly missed by
all who knew him. On a more posrtive note. Anne-marie M¢Alee$e, fomierly of BBC Nl, has joined ug
as an Ambassador for the charity, with a hugely positive impact on all of the events she has organised
or taken part in. We are very grateful for her enthusiastic and ongoing support.
9. 2024 was our 80th anniversary year and we have raised many millions of pounds overlhe$e decades.
We hope our founders would be proud of how the charity has developed over the years, and how we
continue to fund more blood cancer research. These cancers have not gone away. but survival rates
have improved dramatically, along with quality of life. and LLNI has played an important part in a¢hieving
this through the funding of research in Northem Ireland. Overall, Leukaemia and Lymphoma Nl remains
in good shape thanks to the office team and to the input and expertise from our board, and above all
thank5 to our supporters. We are all doing our bit to make blood cancer history.
Public Beneflt
Our main public benefit is in fijnding blood cancer research that would not otheTrMse be taking place.
This has a direct and long teTh benefit for all of those affected by blood cancer by helping to improve
survival rates. The statistics are clear - research has shifted many blood cancers from being fatal, to a
situation where most patients survive and with better quality of life. This could not have happened
without research, and that is what we fijnd. We also provide support for earty career scienlists through
this funding. These scient15ts are the futu￿, and our funding encourages them to stay in Northem Ireland
providing long temi benefit to society through their cancer research. LLNI has become more involved
with lobbying key figures in govemmenl to push for improvements in treatment for blood ¢an¢er patients
in Northern Ireland. which has clear public benefiL The charity also provides information to the public.
part funding a post worktng in local hospitals to do just this. as well as hosting patsent events. all of which
is for the public benefit. LLNI part fijnd a clinical nurse in the City Hospital to better link patients to the
research, and has part funded events to bring scientists together from research instttutes across Ireland.
The board takes great care to follow the Charity Commission's guidance on public benefit when making
decisions, ensuring that all of LLNI'S activities are supportive of this.

Leukaernia & Lymphoma Nl
Company Limited by Guarantee
Trustees. Annual Report (Incorporating the Directors, Report) (conflnued)
Year ended 31 March 2025
Plans for Futuro Periods
The charty has grown steadily over the pasl decade and we aim to conlinue this growth despite the
challenging fundraising environment. We have three staff now, up from just one person a decade ago.
and one of the posts has recently been upgraded to provide more focus on fundraising and
communications. The intention going forward 1$ for this extra $laffing Capacity to focus on enhanced
fundraising through whatever means possible, including more events, and encouragement of major gifts,
legacies and Corporate donations. As part of this we wll continue to grow our online presence. and are
putting more work inlo building relationship$ with a ￿der range of potential donors, with the Clear
message that we are a local charity for local people, but globally connected. Going forward, we intend
to tighten up further on our already good governance in the areas of finance, allocation of funds and
compliance with relevant law and guidance from the Charity Commission for Nl. This work 1$ ongoin9
under the oversight of the board. We also intend to build further our relations with similar charities across
the UK through the Blood Cancer Alliance, and with cancer charities in Nl through the Nl Cancer
Charities Coalition, as well as encouraging enhanced cooperation wth scientists in Ireland. All of this is
with the aim of providing better long temi support for the researchers that we fund. to maximise value
for money from our income, and to ultimately play our part in improving blood cancer survival rates.
Financlal revlew
Details of the results for the period are set out in the statement of financial activities on page 13 and in
the related notes on pages 16 to 25.
Inv8slrnont poll¢y and rotums
LLNI'S investments are managed by Evelyn & Co Stockbrokers Belfast and, including short-term
investments, were valued at £1,014,664 as at 31 March 2025.
During the financial year, we received income from these investments totalling £26,892.
Reserves
The directors have reviewed the resources of LLNI taking into consideration the variable nature of its
income and the need to fulfil the fixed commitment of grants to Queen's University a5 fomali$ed and
confirmed to the University for the period 1 October to 30 September each year. General reseNes at
31si March were £129.920. which represents over 10 months. core expenditure. The Board are
committed to retaining a minimum level of general reserves to cover Six months of day lo day running
costs of the charity.
Trustees. responslbllltles statement
The trustees, who are also directors for the purposes of company law, are responslble for preparing the
trustees, report and the financial statements in accordance with applicable law and United Kingdom
Accounting Standards (United Kingdom Generally Accepted Accounting Practtcel.
Company law requires the charity trustees to prepare financial statements for each year ￿1¢h give a
true and fair view of the state of affairs of the charitable company and the incoming resource5 and
application of re$our¢es, in¢ludin9 the income and expenditure. for that period.

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Trustees, Annual Report (Incorporating the Directors, Report) (cl￿1￿￿￿8dj
Year ended 31 March 2025
Trusteos. responsibilities staternent {continued)
In preparing these financial ststements, the trustee$ are required to..
select suitable accounting policies and then apply them consistently.,
observe the melhods and principles in the applicable Charities SORP.,
make judgements and estimates that are reasonable and prudent.,
prepare the financial statements on the going concem basis unless It Is Inappropriate to
presume Ihat Ihe charity will continue in business.
The trustees are ￿spOnsIble for keeping adequate accounting records that are sufficient to show and
explain the charty's transactions and disclose wth reasonable ac¢ura¢y at any time Ihe financial
position of the charity and enable them to ensure that the financial statements comply wth the
Companies Act 2006. They a￿ also responsible for safeguarding the assets of the charity and hence
for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The charity trustees (who are also the directors of Replay Productions Ltd for the purposes of company
lawl are responsible for preparing the trustees, annual report and the financial statements in accordance
with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted
Accounting Practice).
Company law requires the trustees to prepare accounts for each financial year. Under company law the
trustees must not approve the financial statements unless they are satisfied that they give a true and
fair view of Ihe state of affairs of the charity and the income and expenditure of the charity for that period.
In preparing these accounts, the truslees are required to..
select suitable accounting policies and then apply them consistently-
observe the methods and principles in Ihe Charities SORP;
make judgements and accounting estimates that are reasonable and prudent.,
state whether applicable UK accounting standards have been followed, subject to any material
departures disclosed and explained in Ihe financial statements,. and
prepare the financial statements on the going concern basis unless it is inappropriate to
presume that the charity will continue in operation.
The Irustee$ are responsible for keeping adequate accounting records that a￿ sufficient to show and
explain the charty's transactions and disclose wth reasonable accuracy at any time the financial
position of the charity and enable them to ensure that the financial statements comply with the
Companies Acl 2006. They are also responsible for safeguarding the assets of the charity and hence
for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The trustees are responsible forthe maintenance and integrity of the corporate and financial infomation
in¢luded on the charitable company's website. Legislation in the United Kingdom governing the
preparation and dissemination ot financial statements may differ from legislation in other jurisdictions.

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Trustees, Annual Report (Incorporating the Dire¢tors' Report) {eontlnL*rfJ
Year ended 31 March 2025
Auditor
E8ch of the persons who is a tr￿te8 at thg of approval of this repjrt confirms tbat
so far as each Iruslee Is aware, there is no relevant audit information of which the charity's
auditor is unaware. 2nd
each Iruslee haslakèn 811 st6F6 that they ought to have taken as a trustee lo make themselves
aware ofany re5evant audit information andto estst41sh Ihatthe chanty's audtoris awaig ofthat
information.
Small company provisions
This report has been prepa￿d IA aceordance wlh the wovisions appiicalAe to companies enliljed lo the
small companies exemption.
Thè trustees, annual report was approved on 28th Odoter 2025 and signed on behalf of the board of
trustees by:
Mr R Buchanan
Trustee

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Independent Auditorfs Report to the Members of Leukaemia & Lymphoma Nl
Year ended 3q March 2025
Oplnlon
We have audited the financial statements of Leukaemia & Lymphoma Nl (the'charity'l for the yearended
31 March 2025 which comprise the statement of financial activities (including income and expenditure
account), statement of financial position. statement of cash flows and the related notes, including a
summary of significant a¢¢ounting policies. The financial reporting framework that has been applied in
their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The
Financial Reporting Standard applicable in the UK and Republic of Ireland (Unf(ed Kingdom Generally
Accepted Accounting Practice).
In our opinion the finanaal statements:
give a true and fair view of the state of Ihe ¢harity'$ affrdirs as at 31 March 2025 and of its incoming
resources and application of resources, including ts income and expenditure. for the year then
ended-,
have been properly prepared in accordance ￿ryth United Kingdom Generally Accepted Accounting
Practice.,
have been prepared in accordance )Mth the requirements of the Companies Act 2006.
Basls for opinion
We conducted our audit in a¢¢ordan¢e with Intemational Standards on Auditing (UK) {ISAs (UK)) and
applicable law. Our responsibilities under those standards are further de$¢ribed in the auditorfs
responsibilities for the audit of the financial statements section of our report. We are independent of the
charity in accordance with the ethical requirements that are relevant to our audit of the financial
statements in the UK, including the FRC'S Ethical Standard. and we have futfilled our other ethical
responsibilities in a￿OrdanCe with these requirements. We believe that the audit evidence we have
obtsined 1$ sufficient and appropriate to provide a ba$1$ for our opinion.
Conclusions relating to going concèrn
In auditing the financial statements, we have concluded that the trustees, use of the going concern basis
of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, VR have not identified any material uncertainties relating to
events or conditions that. individualty or collectively, may cast significanl doubt on the charity's ability to
continue as a going concern for a period of at least tWe￿e months from when the )Inancial statements
are authorised for issue.
Our responsibilities and the responsibilitses of the trustees wth respect to going concem are described
in the relevant sections of this report.

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Independent Auditorfs Report to the Members of Leukaemia & Lymphoma Nl
(¢onllnu8d)
Year ended 31 March 2025
oth•r infomiation
The other infomation comprises the information included in the annual report, other than the financial
statements and our auditor's report Ihereon. The trustees are responsible for the other information. Our
opinion on the financial statements does not cover the other infomiation and, except to the extent
othernise explicilty stated in our report, we do not express any forni of assurance conclusion thereon.
In connection with ouraudil of the financial statement$, our responsibility is to read the other infomiation
and, in doing so, consider whether the other infomiation is materially inconsistent vthh the financial
statements or our knowledge obtained in the audit or ¢)therwse appears to be materially misstated. If
we identify such material inconsistencies or apparent material misstatements. we are required to
detsmiine whether there is a material misstatement in the financial statements or a material
misstatement of the other infomation. If. based on the work we have performed. we conclude that there
is a material misstatement of this other infomiation, we are required to report that fact.
We have nothing to report in this regard.
Opinions on othor mattors prns¢ribod by tho Companios Act 2006
In our opinion, based on the work undertaken In the course of the audit-
the information given in the trustees, report for the financial year for which the financial statements
are prepared 15 consistent with the financial statements,. and
the trustees, report ha$ been prepared in accordance wsth applicable legal requirements.
Matters on which wo aro r•qulrod to report by •x¢optlon
In the light of the knowledge and understanding of the charity and its environment obtained in the course
of the audrt. we have not identified material misstatements in the trustees, report.
We have nothing to report in respect of the following matters in relation to which the Companies Act
2006 requires us to report to you if, in our opinion..
adequate accountin9 record5 have not been kept, or retums adequate for our audit have not been
received from branches not visited by us. or
the flnancial statements are not in agreement with the accounting records and retums,. or
certain disclosures of trustees, remuneration specified by law are not made., or
we have not received all the information and explanations require for our audit.

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Independent Audltor's Report to the Members of Leukaemia & Lymphoma Nl
(contlnuéd)
Year ended 31 March 2025
Ro$ponsibilities of truste8S
As explained more fully in the trustees, responslbllities statèment. the trustees (who are also the
directors for the purposes of ¢ompany lawl are responsiblefor the preparation of the financial statements
and for being satisfied that they give a true and fair view, and for such internal control as the Iruslees
determine is necessary to enable the preparation of financial statements that are free from material
misstatement. whether due to fraud or error.
In preparing the financial statements, the trustees are responsible for assessing the charity's ability to
Continue as a going concern, disclosing. as applicable, matters related to going concern and using the
going concem basis of accounting unless the Irustees either intend to liquidate the charity or to cease
operations, or have no realistic alternative but to do so.
Auditotrs rosponslbiliti•$ for the audit of tho financial statsments
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole
are free from material misstatement, whether due to fraud or error, and to issue an auditorfs report that
includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an
audbt conduded in accordance with ISAS {UK) will aknys detect a material misstatement when it exists.
Mi5$tatements can arise from fraud or error and are considered material if, individually or in the
aggregate, they could reasonabty be expected to influence the economic decisions of users tsken on
the basis of these financial statements.
Irregularities. including fraud. are instances of non-compliance with laws and regulations. We design
procedures in line with our responsibilities, outlined above. to detect material misstatements in respect
irregularities, including fraud. The extent to which our procedures are Capable of detecting
irregularities, including fraud is detailed below-
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud
and non-compliance with laws and ￿gUlations. we considered the following=
the natu￿ of the industy and sector. control environment and business perfomiance including the
design of the remuneration policies, key drivers for directors, remuneration, bonus levels and
perfomance targets:
resulls of our enquiries of management about their own identffication and a$$e$$ment of the rlsks
of irregularities:
any matters we ident-ffied having obtained and reviewed documentation of their policies and
procedures relating to..
identrfying, evaluating and Complying with laws and regulations and whether management
were aware of any instances of non-compliance.
detecting and ￿SpOnding to the risks of fraud and whether management have knovledge
of any actual. suspected or alleged fraud,.
the internal controls established to mitigate risks of fraud or nonwcompliance with laws and
regulations.
the matters discussed among the audlt engagement team including significant component audit
teams and relevant intemal specialists. including tax and valuations specialists regarding how and
where fraud might occur in the financial statements and any potential indicators of fraud.
10

Leukaemia & Lymphoma Nl
Company Llmlted by Guarantee
Independent Auditor's Report to the Members of Leukaemia & Lymphoma Nl
(¢ontlnu8(Q
Year ended 31 March 2025
AudIt0￿$ rèsponsibilities for th8 audit of tho Ilnancial statsmonts (continued)
As a resu￿ of these procedures, we considered the opportunities and incentives that may exist within
the organisation for fraud and identified the greatest potential for fraud. In common with all audits under
ISAS (UK), we are also required to perform specific procedures to respond lo the risk of management
override.
We also obtsined an understanding of the legal and regulatory frameworks in operation, fo¢u$ing on
provisions of those laws and regulations that had a direct effect on the detennination of matertal amounts
and disclosures in the financial statements. The key laws and regulations we Considered in this context
included ongoing compliance with the UK Companies Act and tax legislation.
In addition, we considered provisions of other laws and regulations that do not have a direct effect on
the financial statements but ¢omplian¢e with which may be fijndamental for their ability to operate or to
avoid a material penalty.
As part of an audit in a¢cordan¢e with ISAS (UK), we exercise professional judgment and maintsin
professional $cepticism throughout the audit. We also:
Identify and assess the risks of material misstatement of the financial statements. whether due to
fraud or error. design and perform audit pro¢edures responsive to those risks, and obtain audit
evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not
detecting a material misstatement resulting from fraud is higher than for one resulting from error,
as fraud may involve collusion. forgery. intentional omissions, misrepresentatlons, or the override
of intemal control.
Obtsin an understanding of internal control relevantlo the audlt In order to deslgn audit procedures
that are appropriate in the circumstances, bul not for the purpose of expressing an opinion on the
effectiveness of the internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting
estimates and related disclosures made by the trustees.
Conclude on the appropriateness of the trustees, use of the going concern basis of accounting
and. based on the audit evidence obtained, whether a material uncertainty exists related to events
or conditions that may cast significant doubt on the charity's ability to continue as a going concern.
If we conclude that a material uncertainty exists, we are required to draw attention in our auditor'5
report to the related disclosures in the financial statements or. if such disclosures are inadequate,
lo modify our opinion. Our conclusion$ are based on the audit evidence obtained up to the date ot
our auditor's report. However, future events or conditions may cause the charity to cease to
continue as a going concern.
Evaluate the overall presentation, structure and Content of the financial statements. including the
disclosu￿8, and whether the financial statements represent the underfying IranSa￿lOns and events
in a manner that achieves fair presentation.
11

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Independent Auditor's Report to the Members of Leukaemia & Lymphoma Nl
(condnued)
Year ended 31 March 2025
We communicate with those charged with governance regarding. among other matters, the planned
scope and timing of the audit and significant audit findings, including any significant deficiencies in
internal control that we identify during our audit.
Use of our report
This report is made solely tothe charity's members, as a body, in accordance with Chapter 3 ofPart 16
ofthe Companies Act 2006. Our audit work has been undertaken so thatwe might state to the charity's
members those mattèrs we are required to staleto them in an auditorfs report and for no other purpose.
To the fullesl extent permitted by law, we do not accept or assume responsibility lo anyone other than
the charity and the charity's members as a body, for our audit work, for this report, or for the opinions
we have fomied.
Conor Dolan FCA
For and on behalf of..
Finegan Gibson Ltd
Chartered accountants & statutory auditor
Causeway Tower
9 James Street South
Belfast
BT2 8DN
28 October 2025
12

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
statement of Financial Activitles
(including income and expanditure account)
Year ended 31 March 2025
2025
Unrostrictod Restricted
funds
funds Total funds
2024
Total funds
Incorne and endovrtnents
Donations and legacies
Charitable activities
Investment income
other income
465.122
448,732
19,716
50
443,811
26,892
443,811
26,892
Total Incorna
470,703
470,703
933.620
Expendlture
Expenditure on charitable activitie5
Total oxpenditure
9,10
(720,929)
(720,929)
(83,233) (804,162) (635,886)
{83,233) (804,162) (635.886)
Net gains on investments
11
6,177
6,177
16,210
Not {expendlture)Ilncome
(244.049)
(83.233) (327,282)
313,944
Transfers befvften funds
Net movement in funds
(244,049)
(83.233) (327,282)
313,944
Reconciliation of funds
Total fund$ brought forward
Total funds Carried forwdrd
20 1,050.546
187,390
1,237,936
923,992
1,237,936
20
806.497
104.157
910.654
The statement of financial activities includes all gain5 and losses recognised in the year.
All income and expenditure derive from continuing activities.
The notss on pag•$ 16 to 25 forni part of thosg Ilnan¢ial $tatsments.
13

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Statement of Financial Position
31 March 2025
2025
2024
No¢e
Fixed assets
Investments
15
719.977
719,977
714.620
714.S20
Current asset5
Debtors
Short-term investments
Cash at bank ond in hand
16
17
146,CE3
294,687
38.301
332.988
537.379
683,442
Credltors: amounts falling duewlthln one year
Net current assets
{142.3111 1160.1261
190.677
523.316
910.654
910,654
Tolal assets le$5 Current liabillties
1,237,936
1.237,936
Net a55ets
Funds of the charity
Restricted fun
Unrestricted fijnds
19
19
104.157
8C6.497
187,390
1,050.546
1.237.936
Total charity funds
910,654
These finaneial statements were aPF(oved ty the fft￿ard of trustees and authorised for Issue on 28th
O¢lot*T 2025, and are signed on tehalf of the toard by..
Mr R Bu¢hanan
Trustee
The notes on pages 16 10 26 fonn part olthese financlal statemeTrtS.
14

Leukaemia & Lymphoma Nl
Company Limitsd by Guarantee
Statement of Cash Flows
Year ended 31 March 2025
2025
2024
Cash flovds from opornting a¢tivitio8
Net {expenditure)lin¢ome
(327,282)
313,944
Adjustments for
Net gains on investments
Dividends, interest and rents from investments
16.17n
(26,8921
(16,210)
(19,716)
Changes in."
Trade and other debtors
Trade and other creditors
146,063
(17,815)
(232,103)
(35.683)
17,231
Net cash (used inllgenerated from operating activlties
259,566
Cash flows from Investlng actlvltles
Dividends, interest and rents from investrnents
Purchases of other investment5
Pro¢eed5 from sale of other investments
26.892
(211,984)
203,333
18,241
19,716
130,433)
42,636
31.919
Net cash from investing aclNlties
Net decroaso in cash and cash equivalents
Cash and Cash equlvalents at beglnnlng of year
Cash and ¢ash equivalents at end of year
(213,862)
563,936
291,485
272,451
563.936
350.074
The not05 on pag•s 16 to 26 fomi part ofthose finan¢ial $tstements.
15

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Notes to the Financlal Statements
Year ended 31 March 2025
General infomiallon
The charity is a public benefit entty and a private company limited by guarantee. registered in
Northern Ireland and a registered charity in Northern Ireland. The address of the regISte￿d office
is Patrick G Johnston Centre for Cancer Research, 97 Lisburn Road, Belfast. BT9 7AE.
statoment of compliance
These financial statements have been prepared in compliance with FRS 102, The Financial
Reporting Standard appficable in the UK and the Republic of Ireland,, the Statement of
Recommended Practice applicable to charities preparing their accounts in accordance wth the
Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities
SORP {FRS 1021) and the Companies Act 2006.
Accounting policios
Basis of prepardtion
The financial statements have been prepared on the historical cost basis, as modified by the
revaluation of certain financial assets and liabilities and investrnent properttes measured at fair
value through income or expenditure.
The financial statements are prepared in sterling, which is the fvnctional currency of the entity.
Going concern
There are no material uncertainties about the charity's abillty to continue.
Judgements and key sources of ostimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates
and assumptions that affect the amounts reported. These estimates and judgements are reviewed
annually and are based on experience and olher factors. including expectations of future events
that are believed to be reasonable under the circumstances.
Fund accounting
Unrestricted funds are avallable for use at the discretion of the trustees to further any of the
charity's purposes.
Designated fvnds are unrestricted funds earmarked by the trustees for partlcular future projects or
commttments.
Restricted funds are subject to restrictions on their expenditure declared by the donor or through
Ihe tenns of an appeal. and fall into one of two sub-classes: restricted income funds or end0y￿ent
funds.
16

Leuka8mia & Lymphoma Nl
Company Limitsd by Guarantee
Notes to the Financial Statements (¢onllnuedJ
Year ended 31 March 2025
Accounting policies (conrfnuodj
Incomlng rosources
All incoming resources are included in the statement of financial activities when entitlement has
passed to the charity: it is probable that the economic benefits associated wth the transaction will
flow to the charity and the amount can be reliably measured. The following specific policies are
applied to particular categories of income..
income from donations or grants is recognised when there is evidence of entitlement to the
glft, receipt is probable. and its amount can be measured reliably.
legacy Income is recognised when receipt is probable, entitlement is established and they
can be valued wth reasonable accuracy.
income from donated goods is measured at the fair value of the goods unless this is
impractical to measure reliably, in ￿lch case the value is derived from the cost to the donor
or the estimated resale value. Donated facilities and services are recognised in the accounts
when received ff the value can be reliably measured. No amounts are included for the
contribution of general volunteers.
income from contracts for the supply of services is recognised wth the delivery of the
contracted service. This is classified as un￿StriCted funds unless there is a contractual
requirement for it to be spent on a particular purpose and retumed if unspent, in which case
it may be regarded as restricted.
Resourcos oxpondod
Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any
VAT which cannot be fully recovered. and 1$ classified under headings of the statement of financial
activities to which it relate$'.
expenditure on raising funds includes the costs of all fijndraising activities, events, no
charitable trading activities, and the sale of donated goods.
expenditure on charitable activities includes all costs incurred by a charity in undertaking
activities that further it5 charitable aims for the benefit of its beneficiaries. including those
support costs and costs relating to the governance of the charity apportioned to charitable
activitles.
other expenditure includes all expenditure that is neither related to raislng funds forthe charty
nor part of its expenditure on charitable activities.
All costs are allocated to expenditure categories refiecting the use of the resource. Direct costs
attributable to a single activity are allocated directly to that activty- Shared costs are apportioned
be￿een the activities they contribute to on a reasonable. justifiable and consistent basis.
17

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Notes to the Flnancial Statements f¢onlinued)
Year ended 31 March 2025
Accountlng policlos (¢oftllnu
Investments
Investments are stated at market value at the balance sheet date. Net gains or losses Includes
realised and unrealised gains and losses on investments. Realised gains and los$e$ on
investments are calculated as the differences beiween sales prO￿ed$ and their market value at
the start of the year, or their subsequent cost, and are charged or credited to the ststement of
financial activities in the year of disposal. Unrealised gains or10sses represent the movement in
market values during the year and are credited or Charged to the slatement of financial activities
based on the market value at the year end.
The breakdown of non-current inveslments at 31 March was as follows..
2025
2024
Cash
Bond$
Attematives & Multi-Asset
Equities
Total Managed Portfolio
17,086
78,484
133.626
490 781
719,977
26,577
47,008
136,521
504 514
714,620
Short-tem7 inv8Stments
Short-term investments indude short term investments, such as sterling cash liquidity funds and
cash accounts. held through investment managers for the purpose of maximising retums on funds
which are expected to be used in the near temi and are classified as current assets.
Impairmont of fixed assets
A review for indicators of impairment is carried OLrt at each reporting date. with the recoverable
amount being estimated where such indicators exist. Where the carying value exceeds the
recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for
possible reversal at each reporting date.
For the purposes of impairment testing, when it is not possible to estimate the re¢overable amount
of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit
to which the asset belongs. The ¢ash%eneratin9 unit is the smallest identifiable group of assets
that include5 the asset and generates cash infiows that largely independent of the cash inflows
from other assets or groups of assets.
18

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Notes to the Financlal Statements (eonlinued)
Year ended 31 March 2025
Accounting poll¢l8s (eondnued)
Financial In$trurnents
A financial asset or a flnancial liability is recognised only when the charity becomes a party lo the
contractual provisions of the instrument.
Basic financlal instruments are initially recognised at the amount receivable or payable including
any relatsd transaction Costs.
Current assets and current liabilities are subsequentty measured at the cash or other consideration
expected to be paid or received and not discounted. Debt instruments are subsequentty measured
at amortised cost.
Iilthere investments in shares are pubficly traded or their fair value can otherwse be measured
reliably, the investment is subsequentty measured at fair value wth Changes in fair value
recognised in income and expenditure. Al other such investments are subsequently measured at
cost less impairment.
Other financial instruments, including derivatives, are initsally recognised at fair value, unless
payment for an asset is deferred beyond nO￿nal business terms or financed at a rate of interest
that is not a market rate. in which case the asset is measured at the present value of the future
payrnents discounted at a market rate of interest for a similar debt instrument.
Other financial instruments are subsequently measured at fair value, with any changes recognised
in the statement of financial activities, except for hedging instruments in a designated hedging
relationship.
Financial assets that are measured at cost or amorti$ed cost are reviewed for objective evidence
of impairment at the end of each reporting date. If there is objective evidence of impainnent an
impairment loss is recognised under the appropriate heading in the statement of financial activities
in which the initial gain was recognised.
For all equity instruments regardle$$ of significance, and other financial assets that are individually
significant, these are assessed individualty for impaimient. Other financial a$set5 are either
assessed individually or grouped on the basis of similar credit risk characieristi¢$.
Any reversals of impairment are recognised immediately, to the extent that the reversal does not
result in a carying amount of the financial asset that exceeds what the carrying amount would
have been had the impairment not previously been recognised.
19

L8ukaemia & Lymphoma Nl
Company Llmited by Guarantee
Notes to the Financial Statements (eontinuedj
Year ended 31 March 2025
Llmltod by guarantse
The company, being a company limited by guarantee. does not have Sha￿ capital. The liabilty of
members of the company is Ilmited to £1 per member.
Donations andjogaci
Unrestricted
Funds
Restricted Total Funds
Funds
2025
Grants
Grant Income
Unrestricted
Funds
Restricted Total Funds
Funds
2024
Grants
Grant Income
465.122
465,122
Grants of probate were awarded for two legacies during the year, however these have not been
recognised in income or debtors as they cannot be reliably measured. These have been disclosed
as contingent assets in note 22.
Charitable a¢tivitie8
Unrestricted Totsl Funds Unrestricted Total Funds
Funds
2025
Funds
2024
Donations
Legacies
Trading Activities
Branch Income
Stem cell harvest
294,972
23.112
99,094
21,833
4.800
294.972
23,112
99.094
21,833
4.800
347,225
55,154
15.413
25.420
5.520
347,225
55,154
15.413
25,420
5.520
H3,811
443,811
448,732
448.732
Investmènt income
Unrestricted Total Funds Unrestricted Total Funds
Funds
2025
Funds
2024
Investment Incorne
26,892
26,892
19,716
19.718
26,892
26.892
19,716
19,716
Other incomo
Unrestricted Totsl Funds Unrestricted Total Funds
Funds
2025
Funds
2024
Sundry Income
50
50
20

Leukaemia & Lymphoma Nl
Company Llmlted by Guarantee
Notes to the Financial Statements (eontinuedj
Year ended 31 March 2025
Expendlturo on charltable activities by fund type
Unrestricted
Funds
Restrrcted Total Funds
Funds
2025
ChaTitable Activities
720,929
83,233
804,162
Unrestricted
Funds
Restricted Totsl Funds
Funds
2024
Charitable Activities
358,154
277,732
635,886
10. Expendituro on ¢haritabl8 actlvitios by activity type
Activities
undertaken Total funds
directly
2025
Total fund
2024
Charitable Activilies
804.162
804,162
635,886
11. Net gains on Invoslments
Unrestricted Total Funds Unrestricted Totsl Funds
Funds
2025
Funds
2024
Movement on valuation of investments
6.177
6,177
16.210
16,210
12. Auditorfs remu￿ratIon
2025
2024
Fees payable for the audit of the financial statements
5,380
4.975
13. Staff costs
The total staff Costs and employee benefits for the reporting period are analysed as foll¢)ws'.
2025
2024
Wages and salaries
139.125
82,221
LLNI does not employ staff directly, staff are employed by a third paty, Queens University, and
LLNI pays granls towards the $alarie5 of those employees working for LLNI, therefore a breakdown
of the costs belween salaries, pension etc is not possible.
The average head counl of employees during the year was Nil (2024: Nil).
No employee received employee benefits ot more than £60.000 during the year (2024= Nill.
21

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Notes to the Flnancial Statements {coTrlinuedJ
Year ended 31 March 2025
14. Trustee remunfrration and expensos
Trustees did not receive remuneration or reimbursement of expenses during the year (2024: £Nil).
15. Investments
Cash or cash
Listed
equivalents investments
Total
Cost or valuation
At 1 April 2024
Additions
Disposals
Fair value movements
Other movements
26,557
688.063
714,620
211,984
211.984
(203,333) {203.333)
6.663
6,663
{486)
(9,957)
702.891
719,977
(9,471)
17.086
At 31 March 2025
Impaimient
At 1 April 2024 and 31 March 2025
Carrying amount
At 31 March 2025
17,086
702,891
688.063
719.977
At 31 March 2024
26,557
714,620
All investments shown above are held at market value.
Flnancial assets hold at fair value
The listed investments are valued by Evelyn Partners. Belfast and held at market value.
16. Dobtors
2025
2024
Other debtors
146.063
Grants of probate were awarded for two legacies during the year, however these have not been
recognised in income or debtors as they cannot be reliably measured. These have been disclosed
as conlingent assets in note 22.
22

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements {¢onllmiedJ
Year ended 31 March 2025
17. Short4emi Inv￿tMents
Total
Cost or valuation
At 1 April 2024
Additions
Disposals
Income re¢eived
Capital loss
At 31 March 2025
400,000
(110,000)
5,173
(486)
294,687
Carrying arnount
At 31 March 2025
294,687
At 31 March 2024
Short-term investments are held at market value.
18. Credltors: amounts falling due within one year
2025
2024
Accruals and deferred income
142,311
160,126

Leukaernia & Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements (witlnuodj
Year ended 31 March 2025
19. Anatysis of charitablo funds
R89trictod funds
At
1 Apr 2024
Gains and
At
losses 31 Mar 2025
Income Expenditure
Transfers
Research Grant
187.390
187,390
{83,2331
(83,2331
104,157
104.157
At
1 Apr2023
Gains and
At
losses 31 Mar 2024
Income Expenditure
Transfers
PhD Studentship
Research Grant
126,815
338,307
(126.815)
{150,917)
(277.732)
187,390
465,122
187,390
Unrestrlcted funds
At
1 Apr 2024
Gains and
At
losses 31 Mar 2025
Income Expenditure
Transfers
General fund$
Clinic trials nurse
PhD Studentship
Research Gran1$
131,262
58.675
359,246
501.363
1,050,546
470,703
(227.222) 1251,000)
(21,856)
1124,939)
{346.912)
(720,9291
6,177
129.920
36,819
342.307
297.451
108,000
143,000
470,703
6,177
806,497
At
1 Apr2023
Galns and
At
losses 31 Mar 2024
Income Expenditure
Transfers
General fijnds
Clinic trials nurse
PhD Studentship
Research Grants
137,082
80,230
292,314
414,366
923.992
468,498
(130.050) (360,753)
(21,555)
{2.4911
{204,333)
(358.429)
16.485
131,262
58,675
359.246
501,363
16,485 1,050,546
69,423
291.330
468,498
The designated fvnds have been set aside by LLNI as a result ofaward$ of vartous grants approved
by the Board of LLNI for future reSea￿h projects.
24

Leukaemia & Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements I￿ntInue#l
Year ended 31 March 2025
20. Analysis of net assets between funds
Un￿StriCted
Funds
Restricted Total Funds
Funds
2025
Investments
Cu￿ent assets
creditors less than 1 year
Net assets
719,977
208,806
{122,286)
806,497
719,977
332,988
{142,311>
910,654
124.182
(20.025)
104.157
Unrestricted
Funds
Restricted Total Funds
Funds
2024
Investments
Current assets
Creditors less than 1 year
Nat ass•ts
714,620
445.658
(109.732)
1,050.546
714,620
683,442
(160.1261
1.237,936
237,784
(50.394)
187,390
21. Taxation
The Company is a registered charity. and as such is entitled to tax exemplions on income and
profits in furtherance of the charity's primary objectives.
22. Contingent asset
During the year tsvo grants of probate were awarded for residuary legacies in favour of LLNI. There
is Currentty insufficient infonnation available to reasonably determine the residual value of the
estates and therefore these legacies have not been recognised within income or debtors in these
financial statements. One of these legacies has bequeathed signtficant assets to other parties and
it is not yet clear how much. if any. residual amount will remain to be distributed to LLNI. The other
legacy has awarded specific assets to other patknes and it is not clear how much of the overall
estate value these assets make up, therefore the legacy cannot be reliably measured. The
maximum amount LLNI would be expected to receive from this legacy if the value of these specific
assets was negligible would be approximately £287,000. however the actual distribution is
expected to be lower.
23. Contingent liability
A contingent liability exists to repay grants received should certain conditions not be fulfilled by the
Charity. In the opinion of the Trustees. the terms of the Letters of Offers have been, or will be,
complied wth and no liability is expected.
24. Anatysis of changes In net debt
At 1 Apr 2024 Cash flows Al 31 Mar 2025
Cash at bank and in hand
537,379 (499.078)
38.301
25